|M10476||GDC-0575 (ARRY-575)||GDC-0575 (ARRY-575, RG7741) is a potent and selective oral inhibitor of cell cycle checkpoint kinase 1 (Chk1) with an IC50 of 1.2 nM.|
|M10129||CCT245737||CCT245737 is a potent, selective and orally active checkpoint kinase 1 (CHK1) inhibitor, with IC50 values of 1.3 nM, 2440 nM and 30 nM for CHK1, CHK2 and G2 check point abrogation, respectively.|
|M9208||PD0166285||PD0166285 is a potent Wee1 inhibitor and Chk1 inhibitor with IC50s of 24 nM and 72 nM, respectively.|
|M9042||Prexasertib dihydrochloride||Prexasertib dihydrochloride (LY2606368 HCl) is a potent and selective ATP competitive inhibitor of the Chk1 protein kinase with IC50s of <1 nM and 8 nM for CHK1 and CHK2, respectively.|
|M6104||Ipilimumab||Ipilimumab (MDX-010, BMS-734016) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. MW : 148 kD.|
|M5137||BML-277||BML-277 is a high efficient Chk2 inhibitors, IC50 is 15 nM.|
|M3686||AZD7762 hydrochloride||AZD7762 hydrochloride is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.|
|M2325||CHIR-124||CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM.|
|M2324||LY2603618||LY2603618 (IC-83) is a selective Chk1 inhibitor with potential anti-tumor activity.|
|M1996||SCH 900776||SCH 900776 (MK-8776) is a highly potent and functionally selective CHK1 inhibitor with IC50 of 3 nM.|
|M1716||Gemcitabine Hydrochloride||Gemcitabine (Gemzar, LY188011) inhibits DNA synthesis with an IC50 of 0.06 µM.|
|M1698||Clofarabine||Clofarabine inhibits the enzymatic activities of ribonucleotide reductase (IC50 = 65 nM) and DNA polymerase.|
|M1676||BIBR1532||BIBR1532 is a potent and selective telomerase inhibitor with IC50 of 93 nM.|
|M1665||AZD7762||AZD7762 is a potent ATP-competitive checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2 respectively.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.